<DOC>
	<DOCNO>NCT01024777</DOCNO>
	<brief_summary>The purpose study determine safety immunologic effect supplementation low-dose high-dose cholecalciferol ( vitamin D3 ) patient multiple sclerosis .</brief_summary>
	<brief_title>Safety Immunologic Effect Low Dose Versus High Dose Vitamin D3 Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Between age 1855 year ( inclusive ) Serum 25 ( OH ) vitamin D level 2050 ng/mL candidate vitamin D supplementation Patients without immunomodulatory therapy RRMS Diagnosis multiple sclerosis Serum 25 ( OH ) vitamin D deficient level &lt; 20 ng/mL High dose vitamin D supplementation past 3 month Pregnancy History tuberculosis , hyperparathyroidism , sarcoidosis kidney stone Baseline serum creatinine 1.5 Hypersensitivity vitamin D preparation Milk allergy Unable consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>cholecalciferol</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>vitamin D</keyword>
	<keyword>D3</keyword>
</DOC>